8-K: Cellectar Biosciences Announces Positive Q2 Results and Corporate Update, Eyes NDA Filing for Iopofosine

Cellectar Biosciences reported strong Q2 2024 financial results and positive clinical trial data for iopofosine I 131, with plans to file an NDA in Q4 2024.

Summary

• Cellectar Biosciences announced its financial results for the second quarter of 2024, along with a corporate update.
• The company's CLOVER WaM pivotal study for iopofosine I 131 in Waldenstrom's macroglobulinemia (WM) showed an 80% overall response rate (ORR) and a 56.4% major response rate (MRR), exceeding the primary endpoint of 20% MRR.
• The median number of prior lines of therapy for patients in the study was 4, with 27% refractory to all available therapies and 40% dual-class refractory.
• The company plans to file a New Drug Application (NDA) for iopofosine I 131 in the fourth quarter of 2024, anticipating an accelerated six-month review period.
• Cellectar had $25.9 million in cash and cash equivalents as of June 30, 2024, compared to $9.6 million at the end of 2023.
• Net cash used in operating activities for the quarter was approximately $14.1 million.
• The company raised an additional $19.4 million in July and believes its cash is sufficient to fund operations into the second quarter of 2025.
• Research and Development (R&D) expenses for the quarter were $8.2 million, up from $6.3 million in the same period last year.
• General and Administrative (G&A) expenses increased to $6.4 million from $2.0 million in the same period last year, due to commercialization preparation costs.
• A strategic partnership with City of Hope Cancer Center was announced to evaluate iopofosine I 131 in mycosis fungoides, with a trial planned for late 2024 or early 2025.

Sentiment

Score: 9

Explanation: The document conveys a very positive sentiment due to the strong clinical trial results, the upcoming NDA filing, and the improved cash position. The company appears to be on a strong trajectory.

Positives

• The CLOVER WaM study results for iopofosine I 131 were exceptionally positive, demonstrating a high overall response rate and major response rate.
• The duration of response data suggests a durable clinical benefit for patients treated with iopofosine I 131.
• The company's cash position has improved significantly, with $25.9 million in cash and cash equivalents as of June 30, 2024, and an additional $19.4 million raised in July.
• The strategic partnership with City of Hope Cancer Center expands the potential applications of iopofosine I 131.
• The company is on track to file an NDA for iopofosine I 131 in Q4 2024, with an anticipated accelerated review period.

Negatives

• Net cash used in operating activities was approximately $14.1 million for the quarter.
• Research and Development expenses increased to $8.2 million for the quarter, compared to $6.3 million in the same period last year.
• General and Administrative expenses increased significantly to $6.4 million for the quarter, compared to $2.0 million in the same period last year.

Risks

• The company's ability to raise additional capital is a risk factor.
• Disruptions at the sole source supplier of iopofosine could impact the company's operations.
• The company faces risks related to attracting and retaining partners for its technologies.
• There are uncertainties related to the FDA review process and other government regulations.
• The company faces competition from other pharmaceutical companies.
• The volatile market for priority review vouchers is a risk factor.

Future Outlook

The company anticipates an accelerated six-month NDA review period and continues to prepare for a potential launch of iopofosine in 2025. They believe their current cash balance, combined with recent fundraising, is sufficient to fund operations into the second quarter of 2025.

Management Comments

• James Caruso, president and CEO of Cellectar, stated that they remain focused on filing their WM NDA in the fourth quarter of this year.
• James Caruso also mentioned that they anticipate an accelerated six-month NDA review period and continue to prepare for a potential launch of iopofosine in 2025.
• James Caruso expressed the company's desire to establish iopofosine I 131 as the standard of care for the treatment of relapsed and refractory WM patients.

Industry Context

This announcement is significant in the biopharmaceutical industry, particularly in the area of targeted radiotherapeutics for cancer treatment. The positive results from the CLOVER WaM study position Cellectar as a potential leader in the treatment of Waldenstrom's macroglobulinemia. The strategic partnership with City of Hope Cancer Center also highlights the growing interest in exploring new applications for targeted therapies.

Comparison to Industry Standards

• The 80% overall response rate (ORR) and 56.4% major response rate (MRR) in the CLOVER WaM study are very strong compared to typical results for relapsed/refractory Waldenstrom's macroglobulinemia (WM) patients, especially those who have failed multiple prior therapies.
• For example, standard treatments like BTK inhibitors often show lower response rates in later lines of therapy, making Cellectar's results particularly noteworthy.
• Comparable companies developing radiotherapeutics include companies like Bayer and Novartis, but Cellectar's approach with a phospholipid drug conjugate (PDC) delivery platform is unique.
• The median duration of response (DoR) not being reached at the data cutoff, with a high percentage of patients remaining free from disease progression at 18 months, is also a very positive indicator of the potential for iopofosine I 131 to be a durable treatment option.
• The strategic partnership with City of Hope Cancer Center is similar to other collaborations in the industry, where companies partner with leading research institutions to expand the applications of their therapies.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical trial results and the progress towards NDA filing.
• Employees may feel more secure due to the improved financial position and the company's progress.
• Patients with Waldenstrom's macroglobulinemia may have a new treatment option available soon.
• The company's suppliers and partners may benefit from the increased activity and potential commercialization of iopofosine I 131.

Next Steps

• The company plans to file an NDA for iopofosine I 131 in the fourth quarter of 2024.
• They anticipate an accelerated six-month NDA review period.
• The company will continue to prepare for a potential launch of iopofosine in 2025.
• An investigator-sponsored trial for iopofosine I 131 in mycosis fungoides is planned for late 2024 or early 2025.

Key Dates

Keywords

Iopofosine I 131, Waldenstroms macroglobulinemia, CLOVER WaM, NDA, Radiotherapeutic, Cancer, Clinical Trial, Response Rate, Biopharmaceutical, Mycosis Fungoides